Clinical Value of Remote Ischemic Preconditioning
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01740102|
Recruitment Status : Completed
First Posted : December 4, 2012
Last Update Posted : August 4, 2016
|Condition or disease||Intervention/treatment|
|Heart Diseases Atrial Fibrillation||Procedure: RIPC|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||92 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Does Remote Ischemic Preconditioning Reduce the Incidence of Postoperative Atrial Fibrillation in Patient Undergoing Coronary Artery Bypass Graft Surgery?|
|Study Start Date :||August 2012|
|Primary Completion Date :||January 2013|
|Study Completion Date :||September 2013|
Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
No Intervention: No RIPC
Patients in the control group will not receive remote ischemic preconditioning before the surgery.
- Postoperative atrial fibrillation [ Time Frame: Up to 10 days after surgery ]A patient will be classified as belonging to the postoperative atrial fibrillation group if they have any episode of atrial fibrillation, measured by telemetry, lasting more than 1 minute during their postoperative days at the hospital.
- Length of hospital stay [ Time Frame: Maximum 14 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740102
|St Olavs Hospital Trondheim University Hospital|
|Study Director:||Alexander Wahba, MD prof||Faculty of Medicine Norwegian University of Science and Technology Trondheim, Norway, and Department of Cardiothoracic Surgery, St. Olavs Hospital, Trondheim, Norway.|
|Principal Investigator:||Lars Erik B Krogstad||Faculty of Medicine Norwegian University of Science and Technology Trondheim, Norway.|